gastric cancer
Conditions
Interventions
Experimental:apatinib, paclitaxel, S-1
Sponsors
Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Untreated (e.g. chemotherapy, radiotherapy and other antitumor therapy); 2. Aged 18 to 70 years old; 3. Man or female (except pregnant and lactating women); 4. Has been confirmed to with gastric adenocarcinoma; 5. Proven gastric cancer of T stage was T3 and T4, and no distant metastasis was observed. The exfoliative cancer cells detection in peritoneal washes was positive; 6. Blood cell count has to meet the following certeria: WBC=3.5×10^9/L; ANC=1.5×10^9/L; PLT=100×10^9/L; HB=90g/L; 7. Liver/kidney function has to meet the following certeria: ALT and AST=2.5 ULN; TBIL<1.5 ULN; Serum creatinine =1.5 ULN; 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 9. Participants were willing to join in this study, good adherence and written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors within 5 years; 2. Metastasis was found to be visible to the naked eye; 3. It has serious or uncontrolled heart diseases and infections (Including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, poor-controlled hypertension and so on); 4. History of psychiatric drugs abuse and can't quit or patients with mental disorders; 5. Patients with severe or uncontrollable mental illness; 6. Patients with tendency of gastrointestinal bleeding, including the following: a local active ulcerative lesions, and defecate occult blood (+ +).Has melena and hematemesis in two months; 7. Pregnant or lactating women; 8. It have serious harm to the patient's safety or affect the patients who have completed the research. 9. The researchers think inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0-resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Conversion to negative rate;Overall survival (OS) of 3, 5 years;Progression free survival (PFS) of 3, 5 years;safety; | — |
Countries
China
Contacts
Public ContactQun Zhao
Fourth Hospital of Hebei Medical University
Outcome results
None listed